In the weeks surrounding the 2026 annual meeting of the American Society of Clinical Oncology, my phone was flooded with alerts about GLP-1 drugs and cancer. Headlines from NPR, The Washington Post, Substack, and social media debates all echoed a similar assertion: Ozempic might reduce cancer risk.
Those stories are based on a genuine surge of research involving millions of patients. As a physician and clinical epidemiologist, I design and analyze exactly the kind of studies that examine what widely used medications actually do.
The enthusiasm for the idea that GLP-1 drugs can prevent cancer is outpacing the evidence. That does not mean it is wrong—just that the proof is not yet sufficient.
Cancer is among the most difficult subjects to study because it is not a single disease but more than a hundred. Breast, lung, and blood cancers differ fundamentally; each has its own biology and combination of genetic, environmental, and behavioral risks.
No single drug receives one verdict on its cancer effects. It receives many—raising risk for some cancers, lowering it for others, and leaving most unchanged.
The early cancer concerns
Before the current speculation that GLP-1 drugs could lower cancer risk, concern ran the opposite way: that they might increase it.
Researchers first worried about thyroid cancer. Rodent studies found that Ozempic caused thyroid C-cell tumors, prompting U.S. regulators in June 2026 to add a black-box warning against use in those with a personal or family history of related conditions.
But rodents are not humans. Human thyroid C-cells have far fewer GLP-1 receptors and are less sensitive to these drugs. Long-term monkey studies showed none of the abnormal thyroid growth seen in rodents.
A 2025 analysis of 93 clinical trials found no clear link between certain GLP-1 drugs and thyroid cancer. European regulators reached the same conclusion in 2023.
Pancreatic cancer was another worry. A 2025 analysis of 62 studies found no consistent increased risk from GLP-1 use.
The reassurance is real but provisional. These drugs are new, and cancer can take decades to appear.
The cancer story turns on its head
GLP-1 drugs, once investigated for possibly causing cancer, are now discussed as agents that might prevent or treat it.
A 2024 study of over 1.6 million people with Type 2 diabetes found lower rates of 10 of 13 obesity-related cancers among those treated with a GLP-1 drug versus insulin.
A 2025 study of about 87,000 adults found overall cancer rates roughly 17% lower among GLP-1 users, with the clearest reductions in endometrial, ovarian, and meningioma brain cancers. Kidney cancer risk was 38% higher, though larger studies are needed.
Dr. Sutton talks GLP-1 drugs and reduced cancer risk – YouTube
A 2026 study of more than 110,000 women undergoing breast imaging found about 30% lower breast cancer risk among GLP-1 users versus non-users.
Researchers are also examining survival. In a 2024 study of over 6,800 colon cancer patients, about 16% of 103 GLP-1 users died within five years versus 37% of non-users. A 2026 ASCO presentation reported 34% lower death risk across six cancers for GLP-1 users.
Why the evidence is so easy to misread
Although compelling, studies on GLP-1 and cancer risk share three traits that make them easy to misinterpret.
First is healthy user bias. GLP-1 starters tend to be healthier and wealthier. A person with obesity who has insurance, regular care, and can afford Ozempic is more likely to use it than a similar person without those advantages.
This bias is hard to remove from observational studies. The advantages enabling prescription access, not the drug, may explain lower cancer risk.
Second is comparison drug choice. A 2024 study showed large reductions versus insulin, but versus metformin, no clear reduction appeared.
Insulin is for advanced diabetes, itself a cancer risk factor. Comparing to a higher-risk group makes any drug look protective. The benefit came from the comparator, not the GLP-1.
Third is timing. Most GLP-1 studies follow patients only a few years, yet cancer develops over decades. Some show benefits almost immediately—impossible for true prevention. Quick apparent drops suggest users were already lower-risk.
Near-immediate risk reduction is not a drug triumph but a signal of preexisting advantage miscredited to GLP-1s.
Also, almost all data come from high-income countries, even as global uptake rises and cancer burden grows in poorer nations. Broad claims are inferred from narrow data.
What do randomized trials show?
Randomized trials, which equalize groups by design, are the cleanest solution to such biases.
Available trials tell a calmer story. Two 2025 meta-analyses—one of 50 trials, one of 48—found little evidence GLP-1s raise or lower cancer risk.
Meta-analyses are generally more reliable than observational studies due to greater statistical power, but they inherit the trials’ limits: mostly one- to two-year follow-up and too few cancer cases to conclude.
Definitive randomized trials would need tens of thousands of participants followed for years. Until then, observational studies emulating trials offer the next best evidence.
The notion that GLP-1s lower cancer risk remains a hypothesis to test, not a conclusion to act on.
The bottom line
The clearest evidence is reassuring: GLP-1 drugs do not appear to raise overall cancer risk. Claims they prevent cancer or improve survival remain unproven.
If they do affect risk, the mechanism—weight loss, metabolic improvement, or direct effects on inflammation, immunity, or tumors—is unknown.
The surest statement is unsatisfying: it is too early. These drugs are far younger than the cancers they are credited with preventing.
Also Read
- EU Slaps AliExpress With Record €550M Penalty for DSA Violations on Illegal Goods
- New Genomic Risk Tools Suffer from Ancestry Bias, Limiting Accuracy for Diverse Populations
- Peruvian Chancay “False Head” Mask Features Human Hair and Poisonous Cinnabar Pigment
- Silicon Valley’s AI Edge Faces Challenge as China’s Open‑Source Models Surge